Is Cladribine a Suitable Strategy after Natalizumab in MS? Real-world Outcomes (P4-20.007)

Marta Vachova; Dominika Šťastná; Jiří Drahota; Pavel Potužník; Radek Ampapa; Michal Dufek; Markéta Grünermelová; Eva Kubala Havrdova; Jana Houskova; Pavel Hradilek; Jana Libertínová; Alena Martinková; Zbyšek Pavelek; Marek Peterka; Eva Recmanova; Matouš Rous; Zuzana Rous; Ivana Štětkářová; Pavel Stourac; Dana Horakova; Gregor Fistravec

doi:10.1212/wnl.0000000000213265

Key Points

This research evaluates the effectiveness of cladribine compared to natalizumab for disease management in multiple sclerosis.
Real-world data was analyzed from multiple sclerosis patients switching from natalizumab to cladribine.
Short and long-term clinical outcomes were assessed post-transition.
Cladribine showed improved clinical outcomes in disease control after switching from natalizumab.
Patients experienced fewer disease relapses and improved symptom management post-treatment switch.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Real-world trial assesses disease control after switching therapies in multiple sclerosis patients, indicating treatment efficacy.

Abstract

To assess both short and long-term clinical disease control after switching from natalizumab to cladribine in people with multiple sclerosis (pwMS) in real-world practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Vachova et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf393faef96ed7f056198 https://doi.org/10.1212/wnl.0000000000213265

View at Publisher

Ask AI

Bookmark

Share

Is Cladribine a Suitable Strategy after Natalizumab in MS? Real-world Outcomes (P4-20.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Is Cladribine a Suitable Strategy after Natalizumab in MS? Real-world Outcomes (P4-20.007)

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading